BioCartis receives € 1,7M IWT grant for improved disease diagnosis
Biocartis will use this grant to develop, amongst others, its hybrid multiplexing technology aimed at detecting and quantifying multiple biomarker types with a single Idylla™ test. Biocartis is currently developing oncology assays that can already detect tens of biomarkers of the same type. Looking ahead, Biocartis is working on the detection of multiple biomarker types in a single test. Today this can only be accomplished by using several individual tests, often performed on different diagnostic systems or even in separate laboratories, making it a very costly process. The hybrid multiplexing technology opens the door to cost-effective, simultaneous testing of several actionable biomarkers from a single patient sample, allowing precision medicine at affordable cost.
Geert Maertens, Chief Scientific Officer at Biocartis, stated: “The hybrid multiplexing project will strengthen our competitive position in the oncology field and open new opportunities in other disease areas such as infectious and genetic diseases”.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.